25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CASI (CASI Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze CASI Pharmaceuticals Inc together

I guess you are interested in CASI Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – CASI Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – CASI Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of CASI Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about CASI Pharmaceuticals Inc

I send you an email if I find something interesting about CASI Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of CASI Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of CASI Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
$0.12
Expected worth in 1 year
$-5.64
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$-5.76
Return On Investment
-443.2%

For what price can you sell your share?

Current Price per Share
$1.30
Expected price per share
$1.1 - $1.7725
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of CASI Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.30
Intrinsic Value Per Share
$-21.73 - $-1.96
Total Value Per Share
$-21.61 - $-1.84

2.2. Growth of CASI Pharmaceuticals Inc (5 min.)




Is CASI Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1.8m$24.1m-$22.3m-1,205.5%

How much money is CASI Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$39.2m-$26.9m-$12.3m-31.4%
Net Profit Margin-137.6%-79.5%--

How much money comes from the company's main activities?

2.3. Financial Health of CASI Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#714 / 881

Most Revenue
#200 / 881

Most Profit
#751 / 881

Most Efficient
#547 / 881
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of CASI Pharmaceuticals Inc?

Welcome investor! CASI Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of CASI Pharmaceuticals Inc.

First you should know what it really means to hold a share of CASI Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of CASI Pharmaceuticals Inc is $1.3. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of CASI Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in CASI Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.12. Based on the TTM, the Book Value Change Per Share is $-1.44 per quarter. Based on the YOY, the Book Value Change Per Share is $-2.76 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of CASI Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-2.53-194.9%-2.53-194.9%-1.74-133.7%-2.27-174.8%-2.46-189.2%-1.88-144.7%
Usd Book Value Change Per Share-1.44-110.8%-1.44-110.8%-2.76-212.3%-2.28-175.6%-1.19-91.2%0.011.1%
Usd Dividend Per Share0.000.0%0.000.0%0.053.7%0.021.2%0.021.7%0.011.0%
Usd Total Gains Per Share-1.44-110.8%-1.44-110.8%-2.71-208.7%-2.27-174.4%-1.16-89.4%0.032.2%
Usd Price Per Share2.83-2.83-7.16-3.93-3.11-2.80-
Price to Earnings Ratio-1.12--1.12--4.12--1.98--1.44--1.92-
Price-to-Total Gains Ratio-1.96--1.96--2.64--1.76-0.35-0.04-
Price to Book Ratio23.69-23.69-4.59-9.56-5.85-3.00-
Price-to-Total Gains Ratio-1.96--1.96--2.64--1.76-0.35-0.04-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.3
Number of shares769
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share-1.44-1.19
Usd Total Gains Per Share-1.44-1.16
Gains per Quarter (769 shares)-1,107.58-894.22
Gains per Year (769 shares)-4,430.31-3,576.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-4430-444069-3646-3587
20-8861-8870138-7292-7164
30-13291-13300207-10937-10741
40-17721-17730276-14583-14318
50-22152-22160345-18229-17895
60-26582-26590414-21875-21472
70-31012-31020483-25521-25049
80-35442-35450551-29167-28626
90-39873-39880620-32812-32203
100-44303-44310689-36458-35780

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.031.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%15.016.00.048.4%
Dividend per Share0.00.01.00.0%1.00.02.033.3%2.00.03.040.0%3.00.07.030.0%4.00.027.012.9%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%15.016.00.048.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of CASI Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.440-1.4400%-2.760+92%-2.283+59%-1.185-18%0.015-9916%
Book Value Per Share--0.1190.1190%1.560-92%2.000-94%3.931-97%3.620-97%
Current Ratio--1.0861.0860%3.548-69%2.984-64%4.586-76%8.937-88%
Debt To Asset Ratio--0.9660.9660%0.679+42%0.650+49%0.471+105%0.492+96%
Debt To Equity Ratio--27.99727.9970%2.115+1224%10.256+173%6.285+345%3.209+773%
Dividend Per Share----0%0.048-100%0.016-100%0.022-100%0.014-100%
Enterprise Value--8112624.0008112624.0000%90594448.000-91%49491394.667-84%53403436.800-85%63697212.400-87%
Eps---2.534-2.5340%-1.739-31%-2.272-10%-2.460-3%-1.881-26%
Ev To Ebitda Ratio---0.233-0.2330%-4.206+1708%-2.169+832%-2.049+781%-3.171+1263%
Ev To Sales Ratio--0.2840.2840%2.674-89%1.371-79%2.187-87%29.008-99%
Free Cash Flow Per Share---1.902-1.9020%-1.433-25%-1.686-11%-2.142+13%-1.760-7%
Free Cash Flow To Equity Per Share---0.906-0.9060%-1.492+65%-1.444+59%-1.005+11%0.062-1572%
Gross Profit Margin--1.4551.4550%1.611-10%1.476-1%1.389+5%1.200+21%
Intrinsic Value_10Y_max---1.960----------
Intrinsic Value_10Y_min---21.730----------
Intrinsic Value_1Y_max---1.368----------
Intrinsic Value_1Y_min---2.173----------
Intrinsic Value_3Y_max---3.218----------
Intrinsic Value_3Y_min---6.572----------
Intrinsic Value_5Y_max---3.991----------
Intrinsic Value_5Y_min---10.983----------
Market Cap20140640.000-118%43844624.00043844624.0000%110928448.000-60%60835061.333-28%48120636.800-9%43379840.000+1%
Net Profit Margin---1.376-1.3760%-0.795-42%-1.028-25%-1.694+23%-17.195+1150%
Operating Margin---1.304-1.3040%-0.746-43%-0.888-32%-1.227-6%-16.503+1166%
Operating Ratio--2.3882.3880%1.740+37%1.914+25%2.223+7%17.270-86%
Pb Ratio10.881-118%23.68723.6870%4.590+416%9.564+148%5.850+305%3.005+688%
Pe Ratio-0.513+54%-1.117-1.1170%-4.118+269%-1.979+77%-1.445+29%-1.915+72%
Price Per Share1.300-118%2.8302.8300%7.160-60%3.927-28%3.106-9%2.800+1%
Price To Free Cash Flow Ratio-0.684+54%-1.488-1.4880%-4.995+236%-2.507+68%-1.765+19%-2.375+60%
Price To Total Gains Ratio-0.903+54%-1.965-1.9650%-2.639+34%-1.760-10%0.347-666%0.039-5197%
Quick Ratio--0.9340.9340%3.264-71%2.743-66%4.695-80%8.692-89%
Return On Assets---0.731-0.7310%-0.358-51%-0.500-32%-0.452-38%-0.482-34%
Return On Equity---21.209-21.2090%-1.115-95%-7.736-64%-4.884-77%-2.611-88%
Total Gains Per Share---1.440-1.4400%-2.713+88%-2.267+57%-1.163-19%0.028-5199%
Usd Book Value--1851000.0001851000.0000%24165000.000-92%30982666.667-94%60896000.000-97%56084391.300-97%
Usd Book Value Change Per Share---1.440-1.4400%-2.760+92%-2.283+59%-1.185-18%0.015-9916%
Usd Book Value Per Share--0.1190.1190%1.560-92%2.000-94%3.931-97%3.620-97%
Usd Dividend Per Share----0%0.048-100%0.016-100%0.022-100%0.014-100%
Usd Enterprise Value--8112624.0008112624.0000%90594448.000-91%49491394.667-84%53403436.800-85%63697212.400-87%
Usd Eps---2.534-2.5340%-1.739-31%-2.272-10%-2.460-3%-1.881-26%
Usd Free Cash Flow---29464000.000-29464000.0000%-22208000.000-25%-26124000.000-11%-33185400.000+13%-27267010.400-7%
Usd Free Cash Flow Per Share---1.902-1.9020%-1.433-25%-1.686-11%-2.142+13%-1.760-7%
Usd Free Cash Flow To Equity Per Share---0.906-0.9060%-1.492+65%-1.444+59%-1.005+11%0.062-1572%
Usd Market Cap20140640.000-118%43844624.00043844624.0000%110928448.000-60%60835061.333-28%48120636.800-9%43379840.000+1%
Usd Price Per Share1.300-118%2.8302.8300%7.160-60%3.927-28%3.106-9%2.800+1%
Usd Profit---39258000.000-39258000.0000%-26938000.000-31%-35202333.333-10%-41189200.000+5%-31225568.100-20%
Usd Revenue--28537000.00028537000.0000%33879000.000-16%35174333.333-19%30166400.000-5%15501071.200+84%
Usd Total Gains Per Share---1.440-1.4400%-2.713+88%-2.267+57%-1.163-19%0.028-5199%
 EOD+3 -5MRQTTM+0 -0YOY+9 -313Y+8 -325Y+10 -3010Y+9 -31

3.3 Fundamental Score

Let's check the fundamental score of CASI Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.513
Price to Book Ratio (EOD)Between0-110.881
Net Profit Margin (MRQ)Greater than0-1.376
Operating Margin (MRQ)Greater than0-1.304
Quick Ratio (MRQ)Greater than10.934
Current Ratio (MRQ)Greater than11.086
Debt to Asset Ratio (MRQ)Less than10.966
Debt to Equity Ratio (MRQ)Less than127.997
Return on Equity (MRQ)Greater than0.15-21.209
Return on Assets (MRQ)Greater than0.05-0.731
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of CASI Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.493
Ma 20Greater thanMa 501.496
Ma 50Greater thanMa 1001.745
Ma 100Greater thanMa 2001.984
OpenGreater thanClose1.380
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About CASI Pharmaceuticals Inc

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Fundamental data was last updated by Penke on 2025-06-19 01:59:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ CASI Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ CASI Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -137.6%Β means thatΒ $-1.38 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of CASI Pharmaceuticals Inc:

  • The MRQ is -137.6%. The company is making a huge loss. -2
  • The TTM is -137.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-137.6%TTM-137.6%0.0%
TTM-137.6%YOY-79.5%-58.1%
TTM-137.6%5Y-169.4%+31.8%
5Y-169.4%10Y-1,719.5%+1,550.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-137.6%-91.7%-45.9%
TTM-137.6%-139.0%+1.4%
YOY-79.5%-194.4%+114.9%
3Y-102.8%-248.5%+145.7%
5Y-169.4%-343.3%+173.9%
10Y-1,719.5%-488.9%-1,230.6%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ CASI Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ CASI Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -73.1% Return on Assets means thatΒ CASI Pharmaceuticals Inc generatedΒ $-0.73 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of CASI Pharmaceuticals Inc:

  • The MRQ is -73.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -73.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-73.1%TTM-73.1%0.0%
TTM-73.1%YOY-35.8%-37.4%
TTM-73.1%5Y-45.2%-27.9%
5Y-45.2%10Y-48.2%+3.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-73.1%-11.6%-61.5%
TTM-73.1%-11.7%-61.4%
YOY-35.8%-11.4%-24.4%
3Y-50.0%-11.9%-38.1%
5Y-45.2%-12.1%-33.1%
10Y-48.2%-13.8%-34.4%
4.3.1.3. Return on Equity

Shows how efficient CASI Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ CASI Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -2,120.9% Return on Equity means CASI Pharmaceuticals Inc generated $-21.21Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of CASI Pharmaceuticals Inc:

  • The MRQ is -2,120.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2,120.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2,120.9%TTM-2,120.9%0.0%
TTM-2,120.9%YOY-111.5%-2,009.4%
TTM-2,120.9%5Y-488.4%-1,632.5%
5Y-488.4%10Y-261.1%-227.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,120.9%-13.5%-2,107.4%
TTM-2,120.9%-15.0%-2,105.9%
YOY-111.5%-14.5%-97.0%
3Y-773.6%-16.9%-756.7%
5Y-488.4%-17.9%-470.5%
10Y-261.1%-19.9%-241.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of CASI Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient CASI Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit CASI Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ CASI Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of -130.4%Β means the company generated $-1.30 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of CASI Pharmaceuticals Inc:

  • The MRQ is -130.4%. The company is operating very inefficient. -2
  • The TTM is -130.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-130.4%TTM-130.4%0.0%
TTM-130.4%YOY-74.6%-55.7%
TTM-130.4%5Y-122.7%-7.6%
5Y-122.7%10Y-1,650.3%+1,527.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-130.4%-229.2%+98.8%
TTM-130.4%-249.7%+119.3%
YOY-74.6%-208.4%+133.8%
3Y-88.8%-221.7%+132.9%
5Y-122.7%-344.1%+221.4%
10Y-1,650.3%-470.4%-1,179.9%
4.3.2.2. Operating Ratio

Measures how efficient CASI Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 2.39 means that the operating costs are $2.39 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 2.388. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.388. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.388TTM2.3880.000
TTM2.388YOY1.740+0.648
TTM2.3885Y2.223+0.166
5Y2.22310Y17.270-15.048
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3882.108+0.280
TTM2.3882.680-0.292
YOY1.7403.080-1.340
3Y1.9143.621-1.707
5Y2.2234.734-2.511
10Y17.2706.546+10.724
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of CASI Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if CASI Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.09Β means the company has $1.09 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 1.086. The company is just able to pay all its short-term debts.
  • The TTM is 1.086. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.086TTM1.0860.000
TTM1.086YOY3.548-2.462
TTM1.0865Y4.586-3.501
5Y4.58610Y8.937-4.351
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0863.659-2.573
TTM1.0863.834-2.748
YOY3.5484.141-0.593
3Y2.9844.661-1.677
5Y4.5865.756-1.170
10Y8.9376.151+2.786
4.4.3.2. Quick Ratio

Measures if CASI Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ CASI Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.93Β means the company can pay off $0.93 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 0.934. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.934. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.934TTM0.9340.000
TTM0.934YOY3.264-2.330
TTM0.9345Y4.695-3.761
5Y4.69510Y8.692-3.997
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9342.799-1.865
TTM0.9343.143-2.209
YOY3.2643.794-0.530
3Y2.7434.307-1.564
5Y4.6955.707-1.012
10Y8.6926.457+2.235
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of CASI Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of CASI Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ CASI Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.97Β means that CASI Pharmaceuticals Inc assets areΒ financed with 96.6% credit (debt) and the remaining percentage (100% - 96.6%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 0.966. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.966. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.966TTM0.9660.000
TTM0.966YOY0.679+0.287
TTM0.9665Y0.471+0.494
5Y0.47110Y0.492-0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9660.324+0.642
TTM0.9660.347+0.619
YOY0.6790.329+0.350
3Y0.6500.340+0.310
5Y0.4710.349+0.122
10Y0.4920.379+0.113
4.5.4.2. Debt to Equity Ratio

Measures ifΒ CASI Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ CASI Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 2,799.7% means that company has $28.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of CASI Pharmaceuticals Inc:

  • The MRQ is 27.997. The company is unable to pay all its debts with equity. -1
  • The TTM is 27.997. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ27.997TTM27.9970.000
TTM27.997YOY2.115+25.883
TTM27.9975Y6.285+21.712
5Y6.28510Y3.209+3.076
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.9970.379+27.618
TTM27.9970.435+27.562
YOY2.1150.412+1.703
3Y10.2560.446+9.810
5Y6.2850.460+5.825
10Y3.2090.509+2.700
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings CASI Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ CASI Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -1.12 means the investor is paying $-1.12Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of CASI Pharmaceuticals Inc:

  • The EOD is -0.513. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.117. Based on the earnings, the company is expensive. -2
  • The TTM is -1.117. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.513MRQ-1.117+0.604
MRQ-1.117TTM-1.1170.000
TTM-1.117YOY-4.118+3.001
TTM-1.1175Y-1.445+0.328
5Y-1.44510Y-1.915+0.471
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.513-2.282+1.769
MRQ-1.117-2.062+0.945
TTM-1.117-2.541+1.424
YOY-4.118-3.722-0.396
3Y-1.979-3.754+1.775
5Y-1.445-6.100+4.655
10Y-1.915-6.653+4.738
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of CASI Pharmaceuticals Inc:

  • The EOD is -0.684. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.488. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.488. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.684MRQ-1.488+0.805
MRQ-1.488TTM-1.4880.000
TTM-1.488YOY-4.995+3.507
TTM-1.4885Y-1.765+0.277
5Y-1.76510Y-2.375+0.610
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.684-3.101+2.417
MRQ-1.488-2.689+1.201
TTM-1.488-3.594+2.106
YOY-4.995-4.363-0.632
3Y-2.507-5.065+2.558
5Y-1.765-8.478+6.713
10Y-2.375-9.273+6.898
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ CASI Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 23.69 means the investor is paying $23.69Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of CASI Pharmaceuticals Inc:

  • The EOD is 10.881. Based on the equity, the company is expensive. -2
  • The MRQ is 23.687. Based on the equity, the company is expensive. -2
  • The TTM is 23.687. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD10.881MRQ23.687-12.806
MRQ23.687TTM23.6870.000
TTM23.687YOY4.590+19.097
TTM23.6875Y5.850+17.837
5Y5.85010Y3.005+2.845
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD10.8811.932+8.949
MRQ23.6871.848+21.839
TTM23.6872.119+21.568
YOY4.5902.469+2.121
3Y9.5642.526+7.038
5Y5.8503.667+2.183
10Y3.0054.351-1.346
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of CASI Pharmaceuticals Inc.

4.8.1. Institutions holding CASI Pharmaceuticals Inc

Institutions are holding 23.639% of the shares of CASI Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Foresite Capital Management VI LLC8.58071.573132938300
2025-03-31VR Adviser, LLC6.37240.181598725900
2025-03-31Woodline Partners LP1.06090.00231643656467564.8761
2025-03-31Wellington Shields Capital Mgmt LLC0.58670.03569089450595.8939
2025-03-31ADAR1 Capital Management LLC0.30610.0194742011002.3748
2025-03-31Renaissance Technologies Corp0.25110.000138900-500-1.269
2025-03-31Wellington Shields & Co., LLC0.19420.02033009100
2025-03-31Susquehanna International Group, LLP0.1365021143211430
2025-03-31Geode Capital Management, LLC0.12501936300
2024-12-31UBS Group AG0.073011308-3373-22.9753
2025-03-31Royal Bank of Canada0.062609700280040.5797
2025-03-31Morgan Stanley - Brokerage Accounts0.00960149000
2024-12-31Wells Fargo & Co0.00330505-1-0.1976
2025-03-31BlackRock Inc0.0019029600
2025-03-31BNP Paribas Arbitrage, SA0.0009013400
2025-03-31SIMPLEX TRADING, LLC0.000701141140
2025-03-31West Paces Advisors Inc0.00060.000110000
2025-03-31Bank of America Corp0.000406638135.7143
2025-03-31AdvisorNet Financial, Inc0.0002026260
2025-03-31JPMorgan Chase & Co0.000202500
Total 17.7671.83192752582+91081+3.3%

4.9.2. Funds holding CASI Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-04-30Fidelity Nasdaq Composite Index0.12140.000218808-555-2.8663
2025-03-31JNL/DFA US Small Cap A0.01080.0006166900
2025-03-31Dimensional US Small Cap CIT Class S0.00670.0007103400
2025-04-30Dimensional US Sm Company EUR Acc0.0020.000230600
Total 0.14090.001721817-555-2.5%

5.3. Insider Transactions

Insiders are holding 41.452% of the shares of CASI Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-09-08James HuangBUY333004.28
2022-09-06James HuangBUY191623.89
2022-08-26James HuangBUY395273.75
2022-08-24James HuangBUY50003.75
2022-08-22James HuangBUY231053.46
2022-08-19James HuangBUY1711163.27
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-12-312021-12-312022-12-312023-12-312024-12-31
Net Interest Income  866-545321-194127487614-946-332
Total Other Income Expense Net -14,19813,638-560-10,380-10,9409,728-1,2122,7641,552



5.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets53,674
Total Liabilities51,823
Total Stockholder Equity1,851
 As reported
Total Liabilities 51,823
Total Stockholder Equity+ 1,851
Total Assets = 53,674

Assets

Total Assets53,674
Total Current Assets39,576
Long-term Assets13,901
Total Current Assets
Cash And Cash Equivalents 13,468
Short-term Investments 2,623
Net Receivables 15,345
Inventory 5,252
Other Current Assets 2,888
Total Current Assets  (as reported)39,576
Total Current Assets  (calculated)39,576
+/-0
Long-term Assets
Property Plant Equipment 11,360
Long Term Investments 1,716
Intangible Assets 238
Long-term Assets Other 587
Long-term Assets  (as reported)13,901
Long-term Assets  (calculated)13,901
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities36,452
Long-term Liabilities15,371
Total Stockholder Equity1,851
Total Current Liabilities
Short-term Debt 19,606
Short Long Term Debt 18,385
Accounts payable 2,723
Other Current Liabilities 11,649
Total Current Liabilities  (as reported)36,452
Total Current Liabilities  (calculated)52,363
+/- 15,911
Long-term Liabilities
Capital Lease Obligations 3,756
Long-term Liabilities Other 11,821
Long-term Liabilities  (as reported)15,371
Long-term Liabilities  (calculated)15,577
+/- 206
Total Stockholder Equity
Common Stock2
Retained Earnings -700,075
Accumulated Other Comprehensive Income -1,774
Other Stockholders Equity 703,698
Total Stockholder Equity (as reported)1,851
Total Stockholder Equity (calculated)1,851
+/-0
Other
Capital Stock2
Cash and Short Term Investments 16,091
Common Stock Shares Outstanding 15,340
Current Deferred Revenue2,474
Liabilities and Stockholders Equity 53,674
Net Debt 8,673
Net Invested Capital 20,236
Net Working Capital 3,124
Property Plant and Equipment Gross 17,067
Short Long Term Debt Total 22,141



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-311998-12-311997-12-311996-12-311995-12-311994-12-311993-12-311992-12-311991-12-31
> Total Assets 
0
0
0
800
10,100
54,100
47,800
39,600
31,800
31,410
46,218
27,810
40,154
39,404
36,432
55,720
53,015
28,923
10,067
8,037
3,236
8,978
15,508
11,310
5,826
27,713
45,101
113,410
102,631
127,734
138,298
96,234
75,268
53,674
53,67475,26896,234138,298127,734102,631113,41045,10127,7135,82611,31015,5088,9783,2368,03710,06728,92353,01555,72036,43239,40440,15427,81046,21831,41031,80039,60047,80054,10010,100800000
   > Total Current Assets 
0
0
0
200
9,400
53,200
45,900
35,600
27,100
26,476
41,992
24,649
38,161
38,243
35,326
54,867
52,258
28,592
9,874
7,928
3,207
8,908
15,411
11,022
5,569
27,449
43,812
92,565
61,501
74,025
61,970
73,423
59,344
39,576
39,57659,34473,42361,97074,02561,50192,56543,81227,4495,56911,02215,4118,9083,2077,9289,87428,59252,25854,86735,32638,24338,16124,64941,99226,47627,10035,60045,90053,2009,400200000
       Cash And Cash Equivalents 
0
0
0
200
6,900
33,100
18,200
30,800
26,000
24,504
41,386
24,067
34,812
20,425
11,408
20,896
29,676
16,743
6,312
4,886
1,081
8,049
15,132
10,670
5,131
27,093
43,490
84,205
53,621
57,064
38,704
47,112
17,083
13,468
13,46817,08347,11238,70457,06453,62184,20543,49027,0935,13110,67015,1328,0491,0814,8866,31216,74329,67620,89611,40820,42534,81224,06741,38624,50426,00030,80018,20033,1006,900200000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
2,130
14,114
18,675
29,674
18,072
7,548
54
26
0
0
0
0
0
0
0
912
625
9,309
9,868
4,225
13,686
2,623
2,62313,6864,2259,8689,309625912000000026547,54818,07229,67418,67514,1142,130000000000000
       Net Receivables 
0
0
0
0
2,500
0
600
300
700
1,478
234
309
691
3,336
4,905
3,919
4,046
3,918
3,287
2,750
1,933
669
0
24
38
34
242
0
1,293
4,645
9,803
12,973
10,138
15,345
15,34510,13812,9739,8034,6451,293024234382406691,9332,7503,2873,9184,0463,9194,9053,3366913092341,47870030060002,5000000
       Other Current Assets 
0
0
0
0
0
20,100
27,100
4,500
400
494
371
272
528
734
338
756
928
804
442
531
387
189
560
328
438
356
322
8,077
2,840
1,651
1,688
2,975
2,560
2,888
2,8882,5602,9751,6881,6512,8408,0773223564383285601893875314428049287563387345282723714944004,50027,10020,10000000
   > Long-term Assets 
0
0
0
600
700
900
1,900
4,000
4,700
4,934
4,227
3,161
1,993
1,161
1,106
853
757
331
193
109
29
70
96
288
257
264
1,289
20,845
41,130
53,709
76,328
22,811
15,924
13,901
13,90115,92422,81176,32853,70941,13020,8451,2892642572889670291091933317578531,1061,1611,9933,1614,2274,9344,7004,0001,900900700600000
       Property Plant Equipment 
0
0
0
600
800
800
1,500
3,000
4,000
4,576
4,186
3,152
1,992
1,150
915
848
620
264
171
105
25
53
78
262
219
230
1,047
1,751
9,693
10,758
21,819
13,229
11,633
11,360
11,36011,63313,22921,81910,7589,6931,7511,0472302192627853251051712646208489151,1501,9923,1524,1864,5764,0003,0001,500800800600000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,038
29,442
40,128
7,463
1,681
1,716
1,7161,6817,46340,12829,44214,0380000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,785
16,895
13,210
12,203
1,063
1,839
238
2381,8391,06312,20313,21016,89518,785000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
358
41
9
1
11
191
5
136
67
21
5
4
17
18
26
38
34
242
310
504
38,437
2,178
0
0
197
197002,17838,43750431024234382618174521671365191111941358000000000
> Total Liabilities 
0
0
0
600
6,500
6,400
5,700
6,400
9,800
12,353
23,006
17,299
5,278
3,682
7,046
8,739
26,118
23,001
11,993
2,704
704
743
565
11,732
11,914
6,929
6,561
3,948
8,966
24,161
30,339
29,302
51,103
51,823
51,82351,10329,30230,33924,1618,9663,9486,5616,92911,91411,7325657437042,70411,99323,00126,1188,7397,0463,6825,27817,29923,00612,3539,8006,4005,7006,4006,500600000
   > Total Current Liabilities 
0
0
0
600
3,700
4,200
4,500
6,400
7,800
11,347
20,734
16,933
4,755
3,263
6,815
8,598
9,328
13,810
11,269
2,704
704
743
565
919
1,054
1,316
5,062
3,874
7,947
7,976
13,186
17,005
16,726
36,452
36,45216,72617,00513,1867,9767,9473,8745,0621,3161,0549195657437042,70411,26913,8109,3288,5986,8153,2634,75516,93320,73411,3477,8006,4004,5004,2003,700600000
       Short-term Debt 
0
0
0
0
0
100
0
0
1,126
997
1,006
4,865
0
1,416
61
751
2,982
7,708
8,555
757
0
0
0
1,390
4
5,614
1,499
1,499
1,182
2,231
1,061
868
728
19,606
19,6067288681,0612,2311,1821,4991,4995,61441,3900007578,5557,7082,982751611,41604,8651,0069971,1260010000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,390
1,465
1,491
1,499
1,499
0
1,292
0
0
0
18,385
18,3850001,29201,4991,4991,4911,4651,39000000000000000000000000
       Accounts payable 
0
0
0
600
400
600
700
2,100
4,888
8,563
16,309
10,065
3,953
1,550
5,487
5,909
4,551
3,496
1,969
1,351
223
505
402
755
884
1,065
2,088
968
5,113
3,669
4,789
3,289
4,438
2,723
2,7234,4383,2894,7893,6695,1139682,0881,0658847554025052231,3511,9693,4964,5515,9095,4871,5503,95310,06516,3098,5634,8882,100700600400600000
       Other Current Liabilities 
0
0
0
0
3,300
3,500
3,800
4,300
1,787
1,787
3,419
1,892
707
1,617
1,267
1,938
1,795
2,605
745
595
481
238
163
164
165
251
2,974
1,407
1,652
1,642
6,684
10,798
11,079
11,649
11,64911,07910,7986,6841,6421,6521,4072,9742511651641632384815957452,6051,7951,9381,2671,6177071,8923,4191,7871,7874,3003,8003,5003,3000000
   > Long-term Liabilities 
0
0
0
0
2,800
2,200
1,200
0
2,000
1,006
2,272
366
523
420
230
140
16,790
9,191
724
0
0
0
0
10,813
10,860
5,614
1,499
74
1,019
16,185
17,153
12,297
34,377
15,371
15,37134,37712,29717,15316,1851,019741,4995,61410,86010,81300007249,19116,7901402304205233662,2721,0062,00001,2002,2002,8000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,390
1,465
1,491
1,499
0
0
0
0
0
0
0
00000001,4991,4911,4651,39000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
366
523
419
231
141
21
0
0
0
0
0
0
9,423
9,395
4,122
0
74
0
2,351
17,247
0
0
0
00017,2472,35107404,1229,3959,4230000002114123141952336600000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,423
0
0
0
0
0
0
0
0
0
0
00000000009,42300000000000000000000000
> Total Stockholder Equity
0
0
0
300
3,600
47,700
42,000
33,200
22,000
19,040
23,195
10,494
34,859
35,705
29,369
46,963
26,897
5,922
-1,926
5,333
2,532
8,235
14,942
-422
-6,087
20,784
38,540
109,462
72,995
81,540
84,502
44,574
24,165
1,851
1,85124,16544,57484,50281,54072,995109,46238,54020,784-6,087-42214,9428,2352,5325,333-1,9265,92226,89746,96329,36935,70534,85910,49423,19519,04022,00033,20042,00047,7003,600300000
   Common Stock
0
0
0
100
100
0
0
0
100
172
218
241
378
436
511
848
857
885
887
115
122
226
271
325
325
603
699
954
979
1,240
1,399
1
1
2
2111,3991,240979954699603325325271226122115887885857848511436378241218172100000100100000
   Retained Earnings Total Equity000-605,6430-523,900-478,941-452,702-441,932-432,478-425,272-399,0700000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-200
-200
-400
-700
-1,500
-2,300
-3,400
-73
-62
-4,325
-5,711
-102
117
67
-58
-6,144
-6,195
-393
-284
-177
-225
-294
-262
-372
-1,226
-2,728
589
1,954
-703
-1,200
-1,774
-1,774-1,200-7031,954589-2,728-1,226-372-262-294-225-177-284-393-6,195-6,144-5867117-102-5,711-4,325-62-73-3,400-2,300-1,500-700-400-200-200000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
421,775
432,559
434,100
470,147
498,577
596,711
606,686
0
694,826
0
0
0
000694,8260606,686596,711498,577470,147434,100432,559421,7750000000000000000000000
   Treasury Stock000-8,0340-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-8,034-7,667-7,667000000000
   Other Stockholders Equity 
0
0
0
13,200
24,200
73,400
74,500
80,000
104,045
149,855
197,347
220,283
263,943
277,353
287,358
354,284
356,671
359,656
359,964
376,096
377,845
401,341
413,741
424,750
426,359
462,375
490,915
588,676
598,652
650,212
686,792
682,436
686,181
703,698
703,698686,181682,436686,792650,212598,652588,676490,915462,375426,359424,750413,741401,341377,845376,096359,964359,656356,671354,284287,358277,353263,943220,283197,347149,855104,04580,00074,50073,40024,20013,200000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue28,537
Cost of Revenue-17,391
Gross Profit11,14611,146
 
Operating Income (+$)
Gross Profit11,146
Operating Expense-50,767
Operating Income-39,621-39,621
 
Operating Expense (+$)
Research Development8,917
Selling General Administrative23,577
Selling And Marketing Expenses17,866
Operating Expense50,76750,360
 
Net Interest Income (+$)
Interest Income539
Interest Expense-871
Other Finance Cost-0
Net Interest Income-332
 
Pretax Income (+$)
Operating Income-39,621
Net Interest Income-332
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-38,069-41,173
EBIT - interestExpense = -38,069
-38,069
-38,387
Interest Expense871
Earnings Before Interest and Taxes (EBIT)-37,198-37,198
Earnings Before Interest and Taxes (EBITDA)-34,867
 
After tax Income (+$)
Income Before Tax-38,069
Tax Provision-0
Net Income From Continuing Ops-39,258-38,069
Net Income-39,258
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses68,158
Total Other Income/Expenses Net1,552332
 

Technical Analysis of CASI Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of CASI Pharmaceuticals Inc. The general trend of CASI Pharmaceuticals Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine CASI Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. CASI Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of CASI Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.635 < 1.772 < 1.7725.

The bearish price targets are: 1.1.

Know someone who trades $CASI? Share this with them.πŸ‘‡

CASI Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of CASI Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

CASI Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of CASI Pharmaceuticals Inc. The current macd is -0.15635551.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the CASI Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for CASI Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the CASI Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
CASI Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartCASI Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of CASI Pharmaceuticals Inc. The current adx is 18.30.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy CASI Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
CASI Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of CASI Pharmaceuticals Inc. The current sar is 2.46886632.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
CASI Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of CASI Pharmaceuticals Inc. The current rsi is 37.49. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
CASI Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartCASI Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of CASI Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the CASI Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
CASI Pharmaceuticals Inc Daily Stochastic Oscillator ChartCASI Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of CASI Pharmaceuticals Inc. The current cci is -51.90617401.

CASI Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartCASI Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of CASI Pharmaceuticals Inc. The current cmo is -21.74100636.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
CASI Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartCASI Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of CASI Pharmaceuticals Inc. The current willr is -88.56814827.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
CASI Pharmaceuticals Inc Daily Williams %R ChartCASI Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of CASI Pharmaceuticals Inc. The current atr is 0.1936037.

CASI Pharmaceuticals Inc Daily Average True Range (ATR) ChartCASI Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of CASI Pharmaceuticals Inc. The current obv is 19,416,175.

CASI Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartCASI Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of CASI Pharmaceuticals Inc. The current mfi is 84.90.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
CASI Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartCASI Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for CASI Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-05-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

CASI Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of CASI Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.493
Ma 20Greater thanMa 501.496
Ma 50Greater thanMa 1001.745
Ma 100Greater thanMa 2001.984
OpenGreater thanClose1.380
Total1/5 (20.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of CASI Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on CASI Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about CASI Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about CASI Pharmaceuticals Inc

I send you an email if I find something interesting about CASI Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about CASI Pharmaceuticals Inc.

Receive notifications about CASI Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.